Synthesis and structure-activity relationships of a novel series of 2,3,5,6,7,9-hexahydrothieno[3,2-b]quinoline-8(4H)-one 1,1-dioxide K ATP channel openers: Discovery of (-)-(9S)-9-(3-bromo-4-fluorophenyl)-2,3,5,6,7,9-hexahydrothieno[3,2-b] quinolin-8(4H)-one 1,1-dioxide (A-278637), a potent KATP opener that selectively inhibits spontaneous bladder contractions

Journal of Medicinal Chemistry

Volumn 47, Issue 12, 2004, Pages 3163-3179

  Carroll, William A ^a   Altenbach, Robert J ^a   Bai, Hao ^a   Brioni, Jorge D ^a   Brune, Michael E ^a   Buckner, Steven A ^a   Cassidy, Christopher ^a   Chen, Yiyuan ^a   Coghlan, Michael J ^a   Daza, Anthony V ^a   Drizin, Irene ^a   Fey, Thomas A ^a   Fitzgerald, Michael ^a   Gopalakrishnan, Murali ^a   Gregg, Robert J ^a   Henry, Rodger F ^a   Holladay, Mark W ^a   King, Linda L ^a   Kort, Michael E ^a   Kym, Philip R ^a   Milicic, Ivan ^a   Tang, Rui ^a   Turner, Sean C ^a   Whiteaker, Kristi L ^a   Yi, Lin ^a   Zhang, Henry ^a   Sullivan, James P ^a   more..

^a ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 CYANO 1 (1,1 DIMETHYLPROPYL) 3 (3 PYRIDYL)GUANIDINE; 2,3,5,6,7,9 HEXAHYDROTHIENO[3,2 B]QUINOLINE 8(4H) ONE 1,1 DIOXIDE DERIVATIVE; 4 [3,4 DIOXO 2 (1,2,2 TRIMETHYLPROPYLAMINO) 1 CYCLOBUTENYLAMINO] 3 ETHYLBENZONITRILE; 9 (3 BROMO 4 FLUOROPHENYL) 2,3,5,6,7,9 HEXAHYDROTHIENO[3,2 B]QUINOLIN 8(4H) ONE 1,1 DIOXIDE; 9 (3 CYANOPHENYL) 3,4,6,7,9,10 HEXAHYDRO 1,8(2H,5H) ACRIDINEDIONE; A 278637; CROMAKALIM; N (4 BENZOYLPHENYL) 3,3,3 TRIFLUORO 2 HYDROXY 2 METHYLPROPIONAMIDE; POTASSIUM CHANNEL; POTASSIUM CHANNEL STIMULATING AGENT; UNCLASSIFIED DRUG; WAY 133637;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLADDER MUSCLE; CHANNEL GATING; CONCENTRATION RESPONSE; CONTROLLED STUDY; DETRUSOR MUSCLE; DRUG EFFICACY; FEMALE; NONHUMAN; OVERACTIVE BLADDER; SMOOTH MUSCLE RELAXATION; SWINE;

ADENOSINE TRIPHOSPHATE; ANIMALS; CYCLIC S-OXIDES; ELECTRIC STIMULATION; GUINEA PIGS; HEMODYNAMIC PHENOMENA; MEMBRANE POTENTIALS; MUSCLE CONTRACTION; MUSCLE, SMOOTH; POTASSIUM CHANNELS; QUINOLONES; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; SWINE; URINARY BLADDER; URODYNAMICS;

EID: 2542623187     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm030356w     Document Type: Article

References (38)

1. Bosch, J. L. H. R. The overactive bladder: Current aetiological concepts. BJU Int. 1999, 83, 7-9.
2. Brading, A. F. A Myogenic Basis for the Overactive Bladder. Urology 1997, 50, 57-67.
3. Turner, W. H.; Brading, A. F. Smooth Muscle of the Bladder in the Normal and the Diseased State: Pathophysiology, Diagnosis and Treatment. Pharmacol. Ther. 1997, 75, 77-110.
4. Fry, C. H. Discussion: Cellular Physiology of Detrusor Smooth Muscle and the Development of Bladder Instability: Possible Mechanisms. Urology 1997, 50, 70-71.
5. Wein, A. J. Pharmacology of Incontinence. Urol. Clin. N. Am. 1995, 22, 557-577.
6. Wein, A. J. Pharmacological agents for the treatment of urinary incontinence due to overactive bladder. Exp. Opin. Invest. Drugs 2001, 10, 65-83.
7. Wein, A. J.; Longhurst, P. A.; Levin, R. M. Pharmacologic treatment of voiding dysfunction. Urodynamics: Principles, Practice and Application, 2nd ed. ; Churchill Livingston: Edinburgh, 1994; pp 43-70.
8. Lapides, J.; Hodgson, N. B.; Boyd, R. E.; Shook, E. L.; Lichtwardt, J. R. Further Observations on Pharmacologic Reactions of the Bladder. J. Urol. 1958, 79, 707-713.
9. Coghlan, M. J.; Carroll, W. A.; Gopalakrishnan, M. Recent Developments in the Biology and Medicinal Chemistry of Potassium Channel Modulators: Update from a Decade of Progress. J. Med. Chem. 2001, 44, 1627-1653.
10. Andersson, K.-E. The Overactive Bladder: Pharmacologic Basis of Drug Treatment. Urology 1997, 50, 74-84.
11. Nurse, D. E.; Restorick, J. M.; Mundy, A. R. The Effect of Cromakalim on the Normal and Hyperreflexic Human Detrusor Muscle. Brit. J. Urol. 1991, 68, 27-31.
12. ATP Channel Opener with In Vivo Selectivity for Urinary Bladder. J. Pharmacol. Exp. Ther. 1995, 274, 884-890.
13. ATP Potassium Channel Openers. Modifications of the Western Region. J. Med. Chem. 1996, 39, 4592-4601.
14. 2-stimulated bladder activity in conscious rats. J. Urol. 1997, 158, 2300-2304.
15. Butera, J. A.; Antane, M. M.; Antane, S. A.; Argentieri, T. M.; Freeden, C.; Graceffa, R. F.; Hirth, B. H.; Jenkins, D.; Lennox, J. R.; Matelan, E.; Norton, N. W.; Quagliato, D.; Sheldon, J. H.; Spinelli, W.; Warga, D.; Wojdan, A.; Woods, M. Design and SAR of Novel Potassium Channel Openers Targeted for Urge Urinary Incontinence I. N-Cyanoguanidine Bioisosteres Possessing in Vivo Bladder Selectivity. J. Med. Chem. 2000, 43, 1187-1202.
16. ATP Channel Activator. Cardiovasc. Drug Rev. 1997, 15, 220-231.
17. + Channels by Zeneca ZD6169 in Guinea Pig Bladder Smooth Muscle Cells. J. Pharmacol. Exp. Ther. 1997, 280, 38-45.
18. Primeau, J.; Butera, J. A. Potassium Channel Activating Agents; Emerging Trends. Curr. Pharm. Des. 1995, 1, 391-406.
19. Pirotte, B.; Fontaine, J.; Lebrun, P. Recent Advances in the Chemistry of Potassium Channel Openers. Curr. Med. Chem. 1995, 2, 573-582.
20. ATP Channel Openers. Bioorg. Med. Chem. Lett. 1993, 3, 2725-2726.
21. Dodd, J. H.; Schwender, C. F.; Gray-Nunez, Y. Synthesis of Novel Cyclic Sulfone Dihydropyridines Facilitated by a Selective Ethyl Diazoacetate Ring Expansion. J. Heterocycl. Chem. 1990, 27, 1453-1456.
22. ATP) Expressed in Guinea Pig Bladder Smooth Muscle Cells. J. Pharmacol. Exp. Ther. 1999, 289, 551-558.
23. + channels in the pig and human detrusor. Eur. J. Pharmacol. 2000, 400, 287-295.
24. Buckner, S. A.; Milicic, I.; Daza, A. V.; Coghlan, M. J.; Gopalakrishnan, M. Spontaneous phasic activity of the pig urinary bladder smooth muscle: Characteristics and sensitivity to potassium channel modulators, Br. J. Pharmacol, 2002, 135, 639-648.
25. Fey, T. A.; Gopalakrishnan, M.; Strake, J. G.; King, L. L.; Brioni, J. D.; Sullivan, J. P.; Coghlan, M. J.; Brune, M. E. Effects of ATP-Sensitive Potassium Channel Openers and Tolterodine on Unstable Bladder Contractions in a Pig Model of Partial Bladder Outlet Obstruction. Neurol. Urodynamics 2003, 22, 147-155.
26. Vehicle studies demonstrated that the anesthetized pigs maintained a stable baseline cystometrogram for the 90 min study period. For further details of these studies please see ref 25.
27. Mannhold, R. Medicinal Chemistry of DHP-Like Calcium Antagonists. Drugs Today 1994, 30, 103-122.
28. Mills, I. W.; Noble, J. G.; Brading, A. F. Radiotelemetered Cystometry in Pigs: Validation and Comparison of Natural Filling Versus Diuresis Cystometry. J. Urol. 2000, 164, 1745-1750.
29. ATP channel opener, on coronary and systemic haemodynamics in chronically instrumented dogs. Acta Anaesthesiol. Scand. 2000, 44, 1122-1127.
30. The predictive value of the conscious pig CV studies can be appreciated by considering them in the context of data for (-)-cromakalim from a human clinical trial,32 where an average HR increase of 24 ± 7% was recorded 15 min after a maximum plasma concentration of 51 nM was achieved. In these pig studies, an average HR increase for (-)-cromakalim of 38 ± 10% over a 30 min period correlated with a plasma level of 44 nM. Taking into account the variability in the HR and the different sampling times relative to measurement of the physiological effect, this comparison supports these PK/PD relationships for CV effects as predictive for humans.
31. ATP openers showed a weak correlation: slope = 0.47, r = 0.39.
32. Gill, T. S.; Bullman, J. N.; Staniforth, D. H.; Davies, B. E. The pharmacokinetic and haemodynamic effects of cromakalim in man. Br. J. Clin. Pharmacol. 1990, 29, 617P-618P.
33. Rinkes, I. J. On the Identification of 1,4-Disubstituted Hydrocarbons. Recl.-Trav. Chim. Pays-Bas 1945, 64, 205-213.
34. Khanna, I. K.; Weier, R. M.; Yu, Y.; Xu, X. D.; Koszyk, F. J.; Collins, P. W.; Kobolt, C. M.; Veenhuizen, A. W.; Perkins, W. E.; Casler, J. J.; Masferrer, J. L.; Zhang, Y. Y. 1,2-Diarylimidazoles as Potent, Cyclooxygenase-2 Selective, and Orally Active Antiinflammatory Agents. J. Med. Chem. 1997, 40, 1634-1647.
35. Gasco, A. M.; Ermondi, G.; Fruttero, R.; Gasco, A. Benzofurazanyl- and benzofuroxanyl-1,4-dihydropyridines: Synthesis, structure and calcium entry blocker activity. Eur. J. Med. Chem. Chim. Ther. 1996, 31, 3-10.
36. Aldred, R.; Johnston, R.; Levin, D.; Neilan, J. Magnesium-mediated ortho-Specific Formylation and Formaldoximation of Phenols. J. Chem. Soc. Perkin Trans. 1 1994, 13, 1823-1832.
37. B Receptor Antagonists. III Folded Baclofen Analogues Based on Phthalide. Aust. J. Chem. 1989, 42, 787-795.
38. Ashimori, A.; Ono, T.; Uchida, T.; Ohtaki, Y.; Fukaya, C.; Watanabe, M.; Yokoyama, K. Novel 1,4-Dihydropyridine Calcium Antagonists. I. Synthesis and Hypotensive Activity of 4-(Substituted Pyridyl)-1,4-dihydropyridine Derivatives. Chem. Pharm. Bull. 1990, 38, 2446-2458.